Valerio Therapeutics (GB:0NWK)
LSE:0NWK
Want to see GB:0NWK full AI Analyst Report?
0NWK Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EST
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.05 - €0.30
Previous CloseN/A
Volume0.00
Average Volume (3M)57.92K
Market Cap
€92.74M
Enterprise Value€69.28M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta-0.07
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume9,812
30 Day Avg. Volume57,918
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Strong Gross MarginsA ~40.6% revenue rebound coupled with 67–71% gross margins indicates the company’s underlying product economics are favorable. Durable margins for small‑molecule therapeutics imply scalable unit economics if clinical assets advance, supporting longer‑term profitability as revenues scale.
Positive Operating & Free Cash Flow In 2025Turning both operating and free cash flow positive signals an operational inflection and improved cash conversion. This reduces near‑term external financing reliance and demonstrates management can align R&D and operations to generate cash, a durable improvement if maintained through execution.
Focused Clinical-stage Oncology StrategyA focused pipeline targeting DNA/RNA mechanisms creates a clear scientific niche and potential competitive differentiation in oncology. Concentrated R&D efforts with a lean team (38 employees) support efficient resource allocation and make strategic partnerships or licensing a realistic path to scale over the medium term.
Bears Say
High Leverage And Balance-sheet VolatilityElevated leverage (debt/equity ~3.7x) and swings in equity reduce financial flexibility and increase refinancing risk. This structural balance‑sheet weakness makes sustained R&D investment contingent on external financing and raises the chance of dilutive or costly capital solutions over the coming months.
Persistent Net LossesContinued multi‑year net losses (≈‑4.9M in 2025) show the company remains far from consistent profitability despite revenue gains. Ongoing negative earnings imply sustained funding needs for trials and development, limiting free cash accumulation and heightening execution and financing risk.
Inconsistent Cash GenerationVolatile free cash flow despite a recent positive reading indicates cash generation is sensitive to timing of milestones and spending. This inconsistency undermines planning for multi‑phase clinical programs and increases probability of needing external capital, making funding for durable growth uncertain.
0NWK FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest share price was €0.05 and its highest was €0.30 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €92.74M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in GB:0NWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―